Treatment of refractory temporal arteritis with adalimumab

Clinical Rheumatology

Volumn 26, Issue 8, 2007, Pages 1353-1355

  Ahmed, M Mubashir ^a   Mubashir, Eisha ^a   Hayat, Samina ^a   Fowler, Marjorie ^a   Berney, Seth Mark ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

Adalimumab; Corticosteroids; Giant cell arteritis; Temporal arteritis; TNF inhibitors

Indexed keywords

ADALIMUMAB; ATORVASTATIN; C REACTIVE PROTEIN; MECLOZINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; STEROID;

AGED; ARTICLE; BLOOD VESSEL BIOPSY; BLURRED VISION; CASE REPORT; COUGHING; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GIANT CELL ARTERITIS; HEADACHE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC OPTIC NEUROPATHY; LABORATORY TEST; NIGHT SWEAT; OPHTHALMOSCOPY; PHYSICAL EXAMINATION; PNEUMONIA; POSITIONAL VERTIGO; PRIORITY JOURNAL; RELAPSE; TEMPORAL ARTERITIS; THORAX PAIN; UNSTABLE ANGINA PECTORIS; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; WEAKNESS;

ADRENAL CORTEX HORMONES; AGED; ANTIBODIES, MONOCLONAL; BIOLOGICAL RESPONSE MODIFIERS; DRUG RESISTANCE; FEMALE; HUMANS; TEMPORAL ARTERITIS;

EID: 34447124357     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-006-0375-2     Document Type: Article

References (12)

1. Lawrence RC, Helmick CG, Arnett FC et al (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41(5):778-799 (May)
2. Nesher G, Sonnenblick M, Friedlander Y (1994) Analysis of steroid related complications and mortality in temporal arteritis: A 15-year survey of 43 patients. J Rheumatol 21:1283-1286
3. Pipitone N, Boiardi L, Salvarani C (2005) Are steroids alone sufficient for the treatment of giant cell arteritis? Best Pract Res Clin Rheumatol 19(2):277-292 (Apr)
4. Weyand CM, Hicock KC, Hunder GG, Goronzy JJ (1994) Tissue cytokine patterns in polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 121:484-491
5. Field M, Cook A, Gallagher G (1997) Immuno-localisation of tumor necrosis factor and its receptors in temporal arteritis. Rheumatol Int 17:113-118
6. Hernandez-Rodriguez J, Segarra M, Vilardell C et al (2004) Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 43(3):294-301 (Mar)
7. Hernandez-Rodriguez J, Garcia-Martinez A, Filella X et al (2000) IL-6 and TN-α serum concentrations correlate with the intensity of systemic inflammatory response in patients with giant-cell arteritis (abstract). Arthritis Rheum 43:S124
8. Mattey DL, Hajeer AH, Dababneh A, Thomson W, Gonzalez-Gay MA, Garcia-Porrua C et al (2000) Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms. Arthritis Rheum 43:1749-1755
9. Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I (2001) Treatment of longstanding active giant cell arteritis with infliximab: Report of four cases. Arthritis Rheum 44(12):2933-2935 (Dec)
10. Airo P, Antonioli CM, Vianelli M, Toniati P (2002) Anti-tumor necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 41(3):347-349 (Mar)
11. Tan AL, Holdsworth J, Pease C, Emery P, McGonagle D (2003) Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 62(4):373-374 (Apr)
12. Andonopoulos AP, Meimaris N, Daoussis D, Bounas A, Giannopoulos G (2003) Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 62(11):1116 (Nov)